Randy, as regular readers of this blog know, is, or rather was, the President and CEO of CIRM. James Harrison is less well known to the outside world but his imprint on CIRM, as our General Counsel and one of the key figures behind Proposition 71, is even bigger than that of Randy’s. Randy came … Continue reading Emotions and gratitude at changing of the guard at Stem Cell Agency
C. Randal MIlls
CIRM’s Randy Mills leaving stem cell agency to take on new challenge
Some news releases are fun to write. Some less so. The one that CIRM posted today definitely falls into that latter group. It announced that CIRM’s President and CEO, Randy Mills, is leaving us to take up the role of President and CEO at the National Marrow Donor Program – NMPD/Be The Match. It’s a … Continue reading CIRM’s Randy Mills leaving stem cell agency to take on new challenge
Creating a “Pitching Machine” to speed up our delivery of stem cell treatments to patients
When baseball players are trying to improve their hitting they’ll use a pitching machine to help them fine tune their stroke. Having a device that delivers a ball at a consistent speed can help a batter be more consistent and effective in their swing, and hopefully get more hits. That’s what we are hoping our … Continue reading Creating a “Pitching Machine” to speed up our delivery of stem cell treatments to patients
Accelerating the drive for new stem cell treatments
Acceleration is defined as the “increase in the rate or speed of something.” For us that “something” is new stem cell treatments for patients with unmet medical needs. Today our governing Board just approved a $15 million partnership with Quintiles to help us achieve that acceleration. Quintiles was awarded the funding to create a new … Continue reading Accelerating the drive for new stem cell treatments
Why is a cell therapy that restores sight to the blind against the law?
A lot of people are frustrated with the US Food and Drug Administration (FDA) and its woefully slow process for approving stem cell therapies. That’s one of the reasons why we started the CIRM Stem Cell Champions campaign, to gather as many like-minded supporters of stem cell research as possible and help to change the … Continue reading Why is a cell therapy that restores sight to the blind against the law?
What’s the big idea? Or in this case, what’s the 19 big ideas?
Have you ever stood in line in a supermarket checkout line and browsed through the magazines stacked conveniently at eye level? (of course you have, we all have). They are always filled with attention-grabbing headlines like “5 Ways to a Slimmer You by Christmas” or “Ten Tips for Rock Hard Abs” (that one doesn’t work … Continue reading What’s the big idea? Or in this case, what’s the 19 big ideas?
New stem cell approach targeting deadly blood cancers
Every four minutes someone in the US is diagnosed with a blood cancer. It might be lymphoma or leukemia, myeloma or myelodysplastic syndromes (MDS). While we have made great strides in treating some of these over the years, we still have a long way to go. Need proof? Well, every nine minutes someone in the US … Continue reading New stem cell approach targeting deadly blood cancers
If you want to accelerate stem cell therapies then create an Accelerating Center
“You can’t teach fish to fly,” is one of the phrases that our CIRM President & CEO, Randy Mills, likes to throw out when asked why we needed to create new centers to help researchers move their most promising therapies out of the lab and into clinical trials. His point is that many researchers are … Continue reading If you want to accelerate stem cell therapies then create an Accelerating Center
Board gives stem cell institute marching orders, and a road map
The poet T. S. Eliot once wrote: “If you aren't in over your head, how do you know how tall you are?” Well, everyone at CIRM, California’s stem cell institute, is about to find out how tall we are. Yesterday our governing Board approved a new Strategic Plan. To call it ambitious might be considered … Continue reading Board gives stem cell institute marching orders, and a road map
Doing nothing is not OK: A call for change at the FDA
The US Food and Drug Administration (FDA) is caught between a rock and a hard place. And CIRM is going to try and help them get out from under that. As things stand today, if the FDA approves a therapy quickly and a patient later dies from it, then they are widely criticized. If they … Continue reading Doing nothing is not OK: A call for change at the FDA
The Stem Cellar 